690 results about "Reproductive system" patented technology

The invention discloses a probe set for detecting whole exons of extended genetic diseases. The probe set for detecting the whole exons of the extended genetic diseases comprises a standard whole exonprobe set, a whole genome copy number variation probe, and a mitochondrial loop full-length probe, and the genetic diseases comprise 6161 genetic diseases; the standard whole exon probe set can detect the genetic diseases caused by whole exon mutation, the genetic diseases comprise nervous system diseases, metabolic system diseases, endocrine system diseases, digestive system diseases, skeletal system diseases, urinary system diseases, immune system diseases, cardiovascular system diseases, blood system diseases, integument system diseases, ophthalmic system diseases, ear system diseases, respiratory system diseases, and genital system diseases; and the density of the mitochondrial probe is 6X; test samples comprise blood, fresh tissue, FFPE samples, and saliva. The invention discloses using method and kit and application of the probe set for detecting the whole exons of the extended genetic diseases.

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

A method is provided for local controlled delivery of a drug to the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of a patient in need of treatment. In one embodiment, the method includes implanting a resorbable drug delivery device within the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of the patient. The drug delivery device may include an elastic device body housing at least one drug reservoir which contains at least one drug. In a preferred embodiment, the method further includes releasing the drug from the device in a controlled manner to, typically directly to, the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens.

A device and method for male impotence correction and female anorgasmy. An electronic stimulator with at least one pulse generator is implanted inside the body. At least one electrode is installed in the epidural space in the sacrum section of the spinal column and a conductor running under the user's skin electrically connects the electrode to the pulse generator. The stimulator is programmable and may be controlled from outside the body. Upon command initiated by the user or the user's lover the stimulator produces very short low-voltage electrical pulses in the sacrum section that are picked up by the nerves leading to the sex organs of the user, which stimulates arousal in the user's reproductive systems. The pulses are similar to the pulses generated by heart pacemakers. In other preferred embodiments the stimulator includes one or two drug chambers and a tube extending from each chamber to a nerve for producing stimulation of a sex organ. The present invention works on both males and females. In a preferred embodiment, the programmable electronic stimulator is implanted under the skin in the patient's back. Stimulation of the nerves coming out from the parasympathetic part of the spinal cord causes dilatation of the penile arteries in the male and in the clitoris arteries of the female, which results in an erection in the male and pre-orgasmic sensation in the female. In female, the stimulation of the sacral part of the spinal cord increases sexual desire and escalation to the level of orgasm. A preferred embodiment provides for emission stimulation. Emission is stimulated by electrical excitation of the sacral part of the spinal cord by increasing the voltage of the previous impulses. The device may be preprogrammed to set in motion the emission and ejaculation process at a predetermined time interval after the start of the erection process.

Systems and methods define an index of risk for cardiac disease by detecting cellular derangements that may lead to cardiomyopathy, heart rhythm disorders or ischemic heart disease. The markers include fluctuations or abnormal rate-behavior of electrical, mechanical or other measurable biosignals. The invention operates in modes that can be applied to prevent atrial fibrillation or the risk for ventricular arrhythmias. Alternative embodiments are applied to tissue outside the heart such as skeletal muscle, smooth muscle, the central nervous system, the respiratory system, the urogenital system and the gastrointestinal system.

A medical device for performing a surgical procedure may include an elongate member having a proximal end, a distal end, and a lumen extending therebetween. The medical device may also include a handle connected to the proximal end of the elongate member, an end effector assembly connected to the distal end of the elongate member, and a cutting device configured to extend from the end effector assembly, wherein the cutting device has a retracted configuration in which the cutting device is withdrawn into the end effector assembly and a deployed configuration in which the cutting device extends from the end effector assembly.

A surgical apparatus has a body portion that includes a shaft terminating in a distal head or tip for directing light radiation from the apparatus onto the lining of a body cavity for treating an ailment in a body cavity of a patient as for example a gastrointestinal ailment of a patient such as gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric lymphoma, ulcerative colitis, or Crohn's disease as well as for treating diseases of the circulatory system, urogenital systems and other body cavities. During use, the shaft of the apparatus is inserted into a body cavity, e.g., stomach or colon, of the patient to place the distal tip of the shaft in the desired position. The body cavity of the patient is then irradiated with light radiation so as to kill or debilitate microorganisms lining the body cavity without serious destruction of the body tissue of the patient to thereby improve or alleviate one or more of the symptoms of the ailment. A probiotic comprising innocuous bacteria can be administered to the patient to reestablish the growth of normal microbial flora when treating the gastrointestinal tract.

This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist / antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.

The invention discloses a special physiological regulator for maternal animals, and a preparation method thereof, and belongs to the field of feed additive. A technical scheme of the physiological regulator comprises: carrying out crushing and screening for dandelion, leonurus, licorice root and angelica; adding soybean meal and / or wheat bran; adding water to carry out immersing; adjusting pH value of the resulting mixture; carrying out a sterilization; inoculating probiotics to carry out a fermentation after cooling, followed by stoving after completing the fermentation to obtain the physiological regulator. With the prepared physiological regulator for the maternal animals, immunity and disease resistance of the maternal animals are raised, incidence rate of genital system infection is effectively reduced, feed inversion rate is increased, mammogenesis is improved, milk yield is raised, incidence rate of mammitis is reduced, and milk quality is improved. The physiological regulator has characteristics of quick onset, stable and reliable effect, no toxic and side-effect, no pollution, no residue, and no drug resistance generating, and meets requirements of safe feed additive and assurance of foods of animal origin. In addition, the physiological regulator for the maternal animals can be adopted as a veterinary drug through raising using dosage of the physiological regulator, and provides a substantial curative effect for prevention and cure of the mammitis.

Methods and systems for treating patients requiring tissue ablation for volumetric tissue reduction rely on the injection of ethanol and other tissue-ablating agents into the perivascular space surrounding body lumens, particularly blood vessels or vessels of the alimentary canal, reproductive system and urinary tract. Injection of tissue-ablating agents is intended treat conditions such as hypertrophic cardiomyopathy, benign and malignant tumors, benign prostatic hyperplasia, and uterine fibroids, for example. Injection may be achieved using intravascular catheters which advance needles radially outward from a body vessel lumen or by transmyocardial injection from an epicardial or endocardial surface of the heart.

A device and method for male impotence correction and female anorgasmy. An electronic stimulator with at least one pulse generator is implanted inside the body. At least one electrode is installed in the epidural space in the sacrum section of the spinal column and a conductor running under the user's skin electrically connects the electrode to the pulse generator. The stimulator is programmable and may be controlled from outside the body. Upon command initiated by the user or the user's lover the stimulator produces very short low-voltage electrical pulses in the sacrum section that are picked up by the nerves leading to the sex organs of the user, which stimulates arousal in the user's reproductive systems. The pulses are similar to the pulses generated by heart pacemakers. The present invention works on both males and females. In a preferred embodiment, the programmable electronic stimulator is implanted under the skin in the patient's back. Stimulation of the nerves coming out from the parasympathetic part of the spinal cord causes dilatation of the penile arteries in the male and in the clitoris arteries of the female, which results in an erection in the male and pre-orgasmic sensation in the female. In female, the stimulation of the sacral part of the spinal cord increases sexual desire and escalation to the level of orgasm. A preferred embodiment provides for emission stimulation. Emission is stimulated by electrical excitation of the sacral part of the spinal cord by increasing the voltage of the previous impulses. The device may be preprogrammed to set in motion the emission and ejaculation process at a predetermined time interval after the start of the erection process.

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.

The invention provides an oral functional Chinese medicine intensified by snake, bee, macroelement and microelement and its preparation, wherein the preparation is charged by micro and trace element intensifying agent, and at least three Chinese medicinal compositions of snake and honeybee. The preparation can treat various diseases caused by human nourishment imbalance.

A composition and methods for maintaining and restoring normal urogenital flora in humans. The composition includes one or more bacteria selected from the group consisting of Lactobacillus iners, all clones with at least 97% sequence similarity to Lactobacillus iners, Atopobium spp, and all clones with at least 90% sequence similarity to Atopobium spp as determined by sequences from 16S rRNA genes. The method for maintaining includes administering a safe and effective amount of the composition. The method for restoring includes administering a safe and effective amount of an antibiotic and subsequently administering a safe and effective amount of the composition.

Natural and / or synthetic materials to form a strong barrier between the skeletal system and the great vessels. In the preferred embodiments, a natural or synthetic material is used to prevent scar tissue from forming around the vessels and / or to act as barrier placed between the vessels and the skeletal system, including the spine. Devices according to the invention may also be used over the dura and nerves following laminectomy procedures, between the sternum and the pericardium or heart following cardiac procedures, in intra-abdominal procedures such as intestinal or vascular surgery, over the brain in intra-cranial surgery, over the ovaries or other organs or tissues in the female genitourinary system, over the prostate or other organ or tissues in the male genitourinary system, or in other surgeries on humans or animals.

The present invention is directed to cyclic sulfonamide derivatives of formula I:or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behaviorial disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.

The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively. The examples of the diseases include cancer, inflammation, metabolic disease, CVS disease, CNS disease, disorder of hematolymphoid system, disorder of endocrine and neuroendocrine, disorder of urinary tract, disorder of respiratory system, disorder of female reproductive system, and disorder of male reproductive system.

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

[PROBLEMS]To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases.[MEANS FOR SOLVING PROBLEMS]The compound, which is for use as an active ingredient, is represented by the formula (I):[wherein R1 represents optionally halogenated C1-6 alkyl, etc.; R2 represents, e.g., a group represented by the formula (II-1) or (II-4)(wherein W represents C1-6 alkylene, etc. and R represents C1-6 alkyl, etc.); R3 represents hydrogen, C1-6 alkyl, etc.; X represents —O—, —NH—, etc.; and Y1, Y2, Y3, and Y4 each independently represents —CH—, —N—, etc.].

The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in a subject population with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors.The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively. The examples of the diseases include cancer, inflammation, metabolic disease, CVS disease, CNS disease, disorder of hematolymphoid system, disorder of endocrine and neuroendocrine, disorder of urinary tract, disorder of respiratory system, disorder of female reproductive system, and disorder of male reproductive system.

This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus Lactobacillus. More specifically, the invention relates to the utilization of one or more species or strains of Lactobacillus producing bacteria for the control of urinary tract bacteria and pathogens, including antibiotic-resistant urinary tract pathogens, and their associated diseases by both a reduction in the rate of colonization of the infection and pathogens. The method for treatment and relief from symptoms includes administration via a rectal suppository with a safe and effective amount of the composition. The delivery mode for administering the probiotic is via a rectal suppository. The delivery through the rectum provides an optimum method of transmission of the treatment.

A medical device for performing a surgical procedure may include an elongate member having a proximal end, a distal end, and a lumen extending therebetween. The medical device may also include a handle connected to the proximal end of the elongate member, an end effector assembly connected to the distal end of the elongate member, and a cutting device configured to extend from the end effector assembly, wherein the cutting device has a retracted configuration in which the cutting device is withdrawn into the end effector assembly and a deployed configuration in which the cutting device extends from the end effector assembly.

An energy delivery probe is provided that may include any of a number of features. One feature of the energy delivery probe is that it can apply energy to tissue, such as a duct, to shrink, damage, or occlude the duct. In some embodiments, the energy can be applied with a vapor media. In some embodiments, the duct can be a ductus deferens or an ejaculatory duct of the male reproductive system. Another feature of the energy delivery probe is that it can utilize an inflatable member to form a seal to contain the vapor media. Methods associated with use of the energy delivery probe are also covered.

Disclosed are compounds that modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include compounds of the Formulae 1, 2, 3, 4, and 5.

Vaginal or rectal applicators for the delivery of a small volume of pharmaceutical preparation, i.e. less than 1 mL are disclosed herein. The delivery of a small volume of a pharmaceutical preparation allows for the transvaginal delivery of the preparation to the region of the upper vaginal vault or rectum for the treatment of diseases and disorders of the female urogenital system, cervix, uterus, ovaries, fallopian tubes and peritoneal cavity and the lower abdomen. The vaginal or rectal applicators contain four main parts, an applicator barrel, a plunger, a plunger tip, and an applicator cap. The applicator functions similar to a syringe. The applicator is filled with a pharmaceutical preparation with the plunger in the back position. The cap is attached to seal the pharmaceutical preparation in the applicator. To use the applicator, the cap is removed, the applicator is positioned, and the plunger is depressed.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

An apparatus for use in obtaining a woman's reproductive system includes a sheath and a sampler which is telescopically received in the sheath. A proximal end portion of the sampler includes a handle having a bearing surface which tapers in a direction away from the handle. A distal end portion of the sampler includes a brush having bristles with end portions arranged in a sphere. When the sampler is an extended position, the brush is spaced from a distal end portion of the sheath and the bearing surface on the handle is disposed in engagement with a tapered bearing surface on the sheath.